Anthony Meehan

Tony has more than 30 years of experience at both large and small pharmaceutical companies, including Merck, Johnson & Johnson, TransForm Pharmaceuticals, and TetraLogic Pharmaceuticals, with leadership responsibilities across business development, finance, R&D, and manufacturing, including managing teams responsible for development of over 50 investigational molecules and product registrations. He was most recently Chief Business Officer at Venatorx Pharmaceuticals. He joined Lannett Company in 2023 as Chief Financial Officer.

Tony graduated with an M.B.A. from the Wharton School of the University of Pennsylvania, a Ph.D. in chemical engineering from Carnegie Mellon University, and a B.S.E. from the University of Pennsylvania.